Elutia is trading on the Nasdaq stock exchange and requires regulatory clearance from the FDA for product launches.
3 reports, 2 independent
Updated Aug 18
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Elutia is trading on the Nasdaq stock exchange and requires regulatory clearance from the FDA for product launches.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Cellution acquired SimpliDerm business from Elutia, marking its entry into the U.S. reconstructive surgery market.Sub-event
Elutia stock trades on Nasdaq while awaiting FDA regulatory clearance.1 source
Keep exploring
The entities involved
Related events
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.
- Unicycive Therapeutics, Inc. is facing investigator findings regarding manufacturing compliance issues from the FDA.
- PAVmed is facing the requirement of regulatory clearance for its company products, while also attracting institutional investment interest.
- Cisco Systems, Inc. stock trades on the Nasdaq electronic exchange and is subject to required filings with the SEC.